Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant...
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
About this item
Full title
Author / Creator
CanSino COVID-19 Global Efficacy Study Group , Halperin, Scott A , Ye, Lingyun , MacKinnon-Cameron, Donna , Smith, Bruce , Cahn, Pedro E , Ruiz-Palacios, Guillermo M , Ikram, Aamer , Lanas, Fernando , Lourdes Guerrero, M , Muñoz Navarro, Sergio Raúl , Sued, Omar , Lioznov, Dmitry A , Dzutseva, Vitalina , Parveen, Ghazala , Zhu, Fengcai , Leppan, Laura , Langley, Joanne M , Barreto, Luis , Gou, Jinbo , Zhu, Tao , Mao, Helen , Gagnon, Luc , Tran, Steven-Phay , Khan, Sarwat Tahsin , Becerra Aquino, Amalia Guadalupe , Saldaña Montemayor, Edgar Eduardo , Rivera Martínez, Norma Eréndira , Bohórquez López, Víctor Casildo , Simón Campos, J. Abraham , Pineda Cárdenas, Felipe de Jesús , Chen, Wei , Hou, Lihua , Zhang, Zhe , Corral, Gonzalo , López, Eduardo , Teijeiro, Ricardo , Alzogaray, Maria F. , Zaidman, Cesar , Lopardo, Gustavo , Goecke, Bernardo , Feijooó Seoane, Rosa María , Mahmood, Sayed Faisal , Khan, Ejaz Ahmed , Akram, Jayed , Abbas, Salma , Salahuddin, Naseem , Rozhkova, Elena and Zubkova, Tatyana
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial.
This double-blind, randomised, international, placebo-con...
Alternative Titles
Full title
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Authors, Artists and Contributors
Author / Creator
Halperin, Scott A
Ye, Lingyun
MacKinnon-Cameron, Donna
Smith, Bruce
Cahn, Pedro E
Ruiz-Palacios, Guillermo M
Ikram, Aamer
Lanas, Fernando
Lourdes Guerrero, M
Muñoz Navarro, Sergio Raúl
Sued, Omar
Lioznov, Dmitry A
Dzutseva, Vitalina
Parveen, Ghazala
Zhu, Fengcai
Leppan, Laura
Langley, Joanne M
Barreto, Luis
Gou, Jinbo
Zhu, Tao
Mao, Helen
Gagnon, Luc
Tran, Steven-Phay
Khan, Sarwat Tahsin
Becerra Aquino, Amalia Guadalupe
Saldaña Montemayor, Edgar Eduardo
Rivera Martínez, Norma Eréndira
Bohórquez López, Víctor Casildo
Simón Campos, J. Abraham
Pineda Cárdenas, Felipe de Jesús
Chen, Wei
Hou, Lihua
Zhang, Zhe
Corral, Gonzalo
López, Eduardo
Teijeiro, Ricardo
Alzogaray, Maria F.
Zaidman, Cesar
Lopardo, Gustavo
Goecke, Bernardo
Feijooó Seoane, Rosa María
Mahmood, Sayed Faisal
Khan, Ejaz Ahmed
Akram, Jayed
Abbas, Salma
Salahuddin, Naseem
Rozhkova, Elena
Zubkova, Tatyana
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8700283
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8700283
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)02753-7
